4527 On Other Exchanges
Symbol
Exchange
4527 is not on other exchanges.

rohto pharmaceutical co ltd (4527) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROHTO PHARMACEUTICAL CO LTD (4527)

Related News

No related news articles were found.

rohto pharmaceutical co ltd (4527) Related Businessweek News

No Related Businessweek News Found

rohto pharmaceutical co ltd (4527) Details

Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. It offers eye care products, such as eye drops and contact lens; oral medicines comprising gastrointestinal medicines, Chinese herbal medicines, and supplements; dermal medications; regenerative medicines; and non-prescription medicines. The company also operates beauty counters that provide skin care products under the episteme, Obagi, and Hada-Labo brands, as well as beauty care treatments. In addition, it operates an online store, as well as a restaurant, an urban vegetable farm, and a relaxation salon. Rohto Pharmaceutical Co., Ltd. has a partnership agreement with Osaka University's Graduate School of Medicine for the commercialization of mesenchymal stem-cell-based regenerative treatments. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical Co., Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

Founded in 1899

rohto pharmaceutical co ltd (4527) Top Compensated Officers

Chairman of the Board of Directors and Chief ...
Total Annual Compensation: ¥160.0M
Compensation as of Fiscal Year 2016.
rohto pharmaceutical co ltd
Rohto Pharmaceutical Co., Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Earnings Guidance for the First Half and Full Year Ending March 31, 2018

Rohto Pharmaceutical Co., Ltd. announced consolidated and non-consolidated earnings results for the year ended March 31, 2017. For the year, on consolidated basis, the company reported net sales were JPY 154,599 million compared to JPY 167,016 million a year ago. Operating income was JPY 15,451 million compared to JPY 15,683 million a year ago. Ordinary income was JPY 15,964 million compared to JPY 15,339 million a year ago. Profit attributable to owners of parent was JPY 10,011 million or JPY 87.57 diluted per share compared to JPY 9,098 million or JPY 79.70 diluted per share a year ago. ROE was 8.8% compared to 8.3% a year ago. Cash flows from operating activities were JPY 13,428 million compared to JPY 11,324 million a year ago. Profit before income taxes was JPY 14,752 million compared to JPY 14,303 million a year ago. Purchase of property, plant and equipment was JPY 3,777 million compared to JPY 4,563 million a year ago. Purchase of intangible assets was JPY 203 million compared to JPY 168 million a year ago. For the year, on non-consolidated basis, the company reported net sales were JPY 89,561 million compared to JPY 89,264 million a year ago. Operating income was JPY 10,695 million compared to JPY 10,695 million a year ago. Ordinary income was JPY 12,817 million compared to JPY 12,705 million a year ago. Net income was JPY 7,442 million or JPY 65.10 diluted per share compared to JPY 7,118 million or JPY 62.36 diluted per share a year ago. For first half of year ending March 31, 2018, the company expects net sales of JPY 73,000 million, operating income of JPY 6,200 million, ordinary income of JPY 6,500 million and profit attributable to owners of parent of JPY 4,300 million or JPY 37.75 per share. For the year ending March 31, 2018, the company expects net sales of JPY 158,500 million, operating income of JPY 15,600 million, ordinary income of JPY 16,000 million and profit attributable to owners of parent of JPY 10,200 million or JPY 89.54 per share.

Rohto Pharmaceutical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2017, Payable on June 9, 2017; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2018

ROHTO Pharmaceutical Co., Ltd. announced dividend for the fiscal year ended March 31, 2017. For the year, the company announced dividend of JPY 11 per share against JPY 10 per share paid a year ago. Scheduled date of dividend payment is June 9, 2017. For the second quarter of fiscal year ending March 31, 2018, the company expects dividend of JPY 11 per share against JPY 10 per share paid a year ago. For the full year of fiscal year ending March 31, 2018, the company expects dividend of JPY 11 per share against JPY 11 per share paid a year ago.

Rohto Pharmaceutical Co., Ltd. to Report Fiscal Year 2017 Results on May 11, 2017

Rohto Pharmaceutical Co., Ltd. announced that they will report fiscal year 2017 results on May 11, 2017

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4527 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4527.
View Industry Companies
 

Industry Analysis

4527

Industry Average

Valuation 4527 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ROHTO PHARMACEUTICAL CO LTD, please visit www.rohto.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.